Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Clinical Trial

Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session

Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

Benzinga

Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

Benzinga

After-Hours Action: Why Kezar Life Sciences Stock Is Soaring

Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Covid vaccines saved 20 million lives in year - but slow rollout saw 600k die

Almost two-thirds of the world's population has now received at least one dose since the first Covid-19 vaccine was administered outside of a clinical trial

Daily Mirror

Calithera Commences Mid-Stage Study Of DLBCL Candidate

Calithera Biosciences, Inc. (NASDAQ: CALA) initiates dosing first patient in the phase 2 clinical trial evaluating its spleen tyrosine kinase (SYK) inhibitor mivavotinib (CB-659) in patients with relapsed/refractory non-germinal center B-cell like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

Benzinga

UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial

UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease. Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.…

Benzinga

Evaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung Cancer

Evaxion Biotech A/S (NASDAQ:EVAX) has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022. We currently have two product candidates in the DNA technology platform, EVX-02, and EVX-03. Based on preclinical results, the company has decided to move EVX-03…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Rockwell Medical Receives Additional FDA Feedback On Anemia Candidate

Last week, Rockwell Medical Inc (NASDAQ:RMTI) closed the second $7.5 million tranche of the previously announced DaVita Inc (NYSE:DVA) stock purchase agreement of up to $15 million in convertible preferred stock in two tranches. This investment, in addition to the recently announced $15 million financings, brings the total gross amount raised by Rockwell this quarter to $30 million. …

Benzinga

Biomea Fusion Commences Initial-Stage Study For Plasma Cell Cancer Setting

Biomea Fusion (NASDAQ: BMEA) has dosed the the first patient in the multiple myeloma (MM) cohort of the Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor. Multiple myeloma (MM) is a cancer of plasma cells, which make antibodies (immunoglobulins) and are mainly located in the bone marrow.

Benzinga

COVID-19 vaccine from Moderna 'provides good clinical protection' against Omicron subvariants

The biotech company's experimental Omicron booster generates high levels of antibodies that neutralise subvariants BA.4 and BA.5, according to preliminary clinical trial data.

ABC News

Nuvectis Pharma Gets FDA Nod For Initial-Stage Ovarian Cancer Study

The U.S. Food and Drug Administration (FDA) cleared Nuvectis Pharma’s (NASDAQ: NVCT) Investigational New Drug Application (IND) for NXP800, which includes the Phase 1 clinical trial protocol.

Benzinga

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program

LAVA Therapeutics N.V. (NASDAQ:LVTX) hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the American Society of Clinical Oncology and European Hematology Association meetings. "Although preliminary, these data support our view of LAVA-051 as a promising candidate…

Benzinga

Thousands of women with breast cancer could benefit from new NHS-approved pill

A clinical trial found that people taking the drug alongside hormone therapy had a more than 30% better chance of their cancer not coming back

Daily Mirror

Walgreens to launch business that will connect customers with clinical trials

Some Walgreens customers might soon get a new kind of message from the company, asking if they’d like to participate in a clinical trial.

Chicago Tribune

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Walgreens Launches Clinical Trial Business

Walgreens Boots Alliance Inc (NASDAQ:WBA) has launched its clinical trial business to redefine the patient experience and increase access and retention in sponsor-led drug development research. Walgreens will combine the flexible clinical trial model with its vast data on patient insights, partner-enabled health and technology capabilities, and in-person and virtual care options. The…

Benzinga

Plus Therapeutics Concludes Enrolment In Initial-Stage Study Of Cerebrospinal Fluid Cancer Setting

Plus Therapeutics (NASDAQ: PSTV) has concluded patient enrolment in the first cohort of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM).

Tribune News Service

Ivermectin does not shorten COVID-19 illness, according to large Duke clinical trial

RALEIGH, N.C. — Ivermectin does not reduce the length of COVID-19 symptoms or hospitalizations, a large clinical trial headed by Duke researchers suggests.

Benzinga

Can Cannabinoids Work Synergistically In Treatment Of Pain? Here's What One Study Reveals

Radicle Science, an AI-driven healthtech B-corp revealed the results of cannabinoid clinical trial on pain, in partnership with Open Book Extracts (OBX). All formulations in the pain study on CBD and rare cannabinoids were supplied by OBX, a NSF-certified manufacturer and distributor of cannabinoid ingredients and finished products.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Kymera Therapeutics Commences Initial-Stage Oncology Trials

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

Daily Mirror

Dostarlimab cancer drug - how it works as all patients in clinical trial are cured

Cancer diagnoses remain at an all-time high. Statistically, one out of two people will be told they have cancer in their lifetime. Could a new experimental drug be the answer?

Benzinga

Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder

Cybin Inc.

Benzinga

Why Shares Of Cogent Biosciences Are Trading Higher

Cogent Biosciences, Inc. (NASDAQ: COGT) shares are trading higher after the company reported initial data from its ongoing Phase 2 APEX clinical trial.

Benzinga

44 Stocks Moving In Friday's Mid-Day Session

Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.

Benzinga

Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far

Tryp Therapeutics Inc. (OTCQB: TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases.

Benzinga

Cannabis Goes Head-to-Head With Big Pharma In New Zelira Therapeutics Pain Med Study

Zelira Therapeutics (OTC: ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is about to begin a first-ever clinical trial of its own proprietary pain formula for the treatment of diabetic nerve pain against an as-y

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Imperial College London

University of Florida

Walgreens Boots Alliance Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.